Effect of clotrimazole on microsomal metabolism and pharmacokinetics of albendazole.
Albendazole is a broad spectrum anthelmintic drug widely used in human and veterinary medicine. Intestinal and hepatic albendazole metabolism leads to albendazole sulfoxide (active metabolite) and albendazole sulfone (inactive metabolite) formation. Microsomal sulfonase activity can be abolished by in-vitro interaction with clotrimazole and pharmacokinetic studies confirm this interaction. After albendazole incubation, albendazole sulfone formation was completely inhibited by 50 microM clotrimazole in intestinal incubations and a 50% inhibition was observed in hepatic incubations. The lower inhibition constant (K(i)) value observed in the intestinal incubations (9.4 +/- 1.0 microM) compared with the hepatic counterparts (23.3 +/- 15.8 microM) pointed to a greater affinity of the enzymatic systems in the intestine. Regarding the formation of albendazole sulfoxide, an inhibition close to 50% was observed in liver and intestine at 10 microM clotrimazole. The pharmacokinetic parameters obtained following the oral co-administration of albendazole sulfoxide and clotrimazole corroborated the in-vitro inhibition of albendazole sulfone formation, since the ratio of the area under the plasma concentration-time curves for the sulfoxide/sulfone (AUC(ABZSO)/AUC(ABZSO2)) was significantly higher (38.1%). In addition, the AUC and C(max) for albendazole sulfone were significantly lower. The effect of clotrimazole was also studied after prolonged treatment. Hepatic microsomal metabolism of albendazole was induced after 10 days of clotrimazole administration, with significant increases in formation of albendazole sulfoxide (40%) and sulfone (27%). These results offer further insight into the metabolism of benzimidazole drugs and highlight the difficulty involved in human therapy with these anthelmintics, since after prolonged treatment the drug interactions are affected differentially.
Merino
G
G
Department of Physiology, Veterinary Faculty, University of Leon, 24071 Leon, Spain.
Molina
A J
AJ
García
J L
JL
Pulido
M M
MM
Prieto
J G
JG
Alvarez
A I
AI
D000284:Administration, Oral; D015766:Albendazole / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D000818:Animals; D000871:Anthelmintics / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000494:pharmacology*; D019540:Area Under Curve; D001711:Biotransformation; D003022:Clotrimazole / Q000494:pharmacology*; D004347:Drug Interactions; D006207:Half-Life; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D000871:Anthelmintics; D000935:Antifungal Agents; C027187:albendazole sulfone; D015766:Albendazole; D003022:Clotrimazole; C027186:albendazole sulfoxide